1. Assessing the Quality of Pharmacoeconomic Studies in India

   • Pooja R. Desai
   • Hitesh S. Chandwani
   • Karen L. Rascati

   Systematic Review 27 December 2012 Pages: 749 - 762

   

2. Cost of Illness of Cystic Fibrosis in Germany

   • Mareike Heimeshoff
   • Helge Hollmeyer
   • Doris Staab

   Original Research Article 27 December 2012 Pages: 763 - 777

   

3. Reimbursement Decisions of the All Wales Medicines Strategy Group

   • Warren G. Linley
   • Dyfrig A. Hughes

   Original Research Article 27 December 2012 Pages: 779 - 794

   

4. Lost Productivity in Four European Countries among Patients with Rheumatic Disorders

   • Saskia Knies
   • Math J. J. M. Candel
   • Johan L. Severens

   Original Research Article 27 December 2012 Pages: 795 - 807

   

5. Costs Associated with Febrile Neutropenia in the US

   • Shannon L. Michels
   • Rich L. Barron
   • Gary H. Lyman

   Original Research Article 27 December 2012 Pages: 809 - 823

   

6. A Lifetime Markov Model for the Economic Evaluation of Chronic Obstructive Pulmonary Disease

   • Petra Menn
   • Reiner Leidl
   • Rolf Holle

   Original Research Article 27 December 2012 Pages: 825 - 840

   

7. Dabigatran Etexilate

   • Kate McKeage

   Adis Pharmacoeconomic Drug Evaluation 27 December 2012 Pages: 841 - 855

   

8. Caregivers’ Quality of Life and Economic Evaluations

   • Afschin Gandjour

   Correspondence 27 December 2012 Pages: 857 - 858

9. The Authors’ Reply

   • Hareth Al-Janabi
   • Terry N. Flynn
   • Joanna Coast

   Correspondence 27 December 2012 Pages: 858 - 858